Opioid Use Disorder: Treatments and Barriers.
non-pharmacological treatment
opioids use disorder
pharmacological treatment
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
06 Feb 2021
06 Feb 2021
Historique:
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
Over the last decade, opioid use around the world has risen considerably and is projected to continue to rise at an alarming rate. As opioid use rises, so too does the number of people who suffer from opioid use disorder (OUD) and opioid overdose-related deaths. As science and medicine progresses, new medications and therapies have arisen in order to help treat patients suffering from addiction. Treatment can be split into two main domains: pharmacological and non-pharmacological. Buprenorphine and methadone, currently the most prescribed medications for patients suffering from OUD, have been shown to be extremely effective in clinical trials but have significant real-world limitations. Geographical disparities between various locations, physician stigma with prescribing these medications, and training required to prescribe medication can make access to these treatments difficult for patients. Non-pharmacological interventions have also been shown to help with limited efficacy when combined with pharmacological interventions. However, the time and resources required to implement these strategies may be a difficult barrier to overcome. In this review, we assess pharmacological interventions, non-pharmacological treatments, examine barriers to treatment for patients, and propose solutions to bypass these barriers.
Identifiants
pubmed: 33717718
doi: 10.7759/cureus.13173
pmc: PMC7938868
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e13173Informations de copyright
Copyright © 2021, Patel et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Br J Gen Pract. 2000 May;50(454):385-6
pubmed: 10897536
JAMA Netw Open. 2020 Feb 5;3(2):e1920622
pubmed: 32022884
PLoS One. 2015 Jun 24;10(6):e0127598
pubmed: 26107818
J Addict Med. 2019 Mar/Apr;13(2):93-103
pubmed: 30531584
Am J Addict. 2014 Nov-Dec;23(6):618-22
pubmed: 25065457
Am J Psychother. 2006;60(3):233-59
pubmed: 17066756
JAMA. 2016 Nov 15;316(19):2008-2024
pubmed: 27838722
Drug Alcohol Depend. 2019 Jan 1;194:460-467
pubmed: 30508769
Am J Prev Med. 2018 Jun;54(6 Suppl 3):S230-S242
pubmed: 29779547
Clin Pharmacol Ther. 1989 May;45(5):513-9
pubmed: 2721107
JAMA Netw Open. 2019 Feb 1;2(2):e187621
pubmed: 30707224
CNS Drugs. 2019 Jun;33(6):567-580
pubmed: 31062259
Health Soc Care Community. 2007 May;15(3):238-45
pubmed: 17444987
MMWR Morb Mortal Wkly Rep. 2014 Oct 3;63(39):849-54
pubmed: 25275328
Drug Alcohol Depend. 2013 Jul 1;131(1-2):23-35
pubmed: 23490450
J Clin Nurs. 2008 Sep;17(18):2452-62
pubmed: 18547349
Can Med Assoc J. 1973 Oct 6;109(7):615-9
pubmed: 4599599
Psychiatr Clin North Am. 2010 Sep;33(3):511-25
pubmed: 20599130
Ochsner J. 2014 Summer;14(2):208-15
pubmed: 24940131
J Clin Oncol. 2004 Jan 1;22(1):185-92
pubmed: 14701781
Addiction. 2006 Nov;101(11):1546-60
pubmed: 17034434
MMWR Morb Mortal Wkly Rep. 2011 Nov 4;60(43):1487-92
pubmed: 22048730
J Clin Anesth. 2002 Jun;14(4):284-9
pubmed: 12088813
Addict Sci Clin Pract. 2012 Jun 09;7:10
pubmed: 23186149
J Gen Intern Med. 2020 Apr;35(4):1304-1306
pubmed: 32076988
Psychiatrist. 2011 May;35(5):161-163
pubmed: 22558006
Am Fam Physician. 2017 Mar 1;95(5):Online
pubmed: 28290640
JAMA. 2019 Apr 16;321(15):1446-1447
pubmed: 30990541
MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):837-43
pubmed: 27560775
Perspect Behav Sci. 2019 Jul 9;42(3):445-464
pubmed: 31976444
Am J Drug Alcohol Abuse. 2020 Sep 2;46(5):520-530
pubmed: 32960649